Heart. Published Online First: 10 April 2006. doi:10.1136/hrt.2006.088427
Editorials |
The role of vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention
1 Wellington Hospital, New Zealand
* To whom correspondence should be addressed. E-mail: scottaharding{at}slingshot.co.nz.
Accepted 19 March 2006
Abstract
The majority of studies examining the role of vasodilators in the prevention or treatment of no-reflow following PCI have demonstrated improvements in surrogate endpoints such as TIMI flow rate, TIMI frame count and wall motion scores. However, their effect on important clinical endpoints such as mortality and heart failure remains uncertain.
Keywords: adenosine, no-reflow, vasodilators, verapamil
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Relevant Articles
-
Web Top 10
Heart 2006 92: 1865.[Extract] [Full Text] [PDF]
-
Web Top 10
Heart 2006 92: 1691.[Extract] [Full Text] [PDF]
- Full Text (Rapid PDF)
-
All Versions of this Article:
hrt.2006.088427v1
92/9/1191 most recent - Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
